Cancer became recently the leading cause of death in industrialized countries. Even though
standard treatments achieve significant effects in growth inhibition and tumor elimination …

Cancer is considered as one of the most serious health problems today. The discovery of
nitrogen mustard as an alkylating agent in 1942, opened a new era in the cancer …

In cancer, one of the main barriers to effective chemotherapy is inefficient drug delivery. The
delivery of drugs to solid tumors involves various biochemical, biophysical, and mechanical …

Abstract Background Peptide-drug-conjugates (PDCs) are being developed as an effective
strategy to specifically deliver cytotoxic drugs to cancer cells. However one of the challenges …

In recent years, targeted therapies have raised increasing interest as effective strategies to
improve therapeutic efficiency, reduce the impact of adverse side effects, and overcome …

More than 100 years ago, German physician Paul Ehrlich first proposed the concept of
selectively delivering “magic bullets” to tumors through targeting agents. The targeting …

Many anticancer drugs exhibit high systemic off-target toxicities causing severe side effects.
Peptide–drug conjugates (PDCs) that target tumor-specific receptors such as integrin αvβ6 …

RGD peptides have received a lot of attention over the two last decades, in particular to
improve tumor therapy through the targeting of the αVβ3 integrin receptor. This review …

While the advent of nano-engineered drug delivery systems (DDSs) has revived hopes for
better management of a wide range of pathologies, critical appraisal of the field has shown …

Targeted delivery of chemotherapeutics and diagnostic agents conjugated to carrier ligands
has made significant progress in recent years, both in regards to the structural design of the …